Trials / Completed
CompletedNCT01151813
Human Behavioral Pharmacology Laboratory (HBPL) Study of Varenicline's Impact on Cocaine and Alcohol Craving
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 15 (actual)
- Sponsor
- University of Pennsylvania · Academic / Other
- Sex
- All
- Age
- 21 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase II within-subjects double-blind placebo-controlled human laboratory study. The purpose of the study is to determine the efficacy of varenicline (Chantix) for reducing cue-induced cocaine and alcohol craving.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Varenicline | Varenicline, oral target dose of 1.0 mg BID, one week titration. |
| DRUG | Placebo | Placebo |
Timeline
- Start date
- 2010-07-01
- Primary completion
- 2013-08-01
- Completion
- 2013-12-01
- First posted
- 2010-06-28
- Last updated
- 2020-08-18
- Results posted
- 2020-08-18
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01151813. Inclusion in this directory is not an endorsement.